Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1% - Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s share price was down 8.1% during mid-day trading on Friday . The stock traded as low as $23.18 and last traded at $23.43. Approximately 54,709 shares were traded during trading, a decline of 73% from the average daily volume of 202,782 shares. The stock had previously closed at $25.49.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Raymond James increased their price target on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an "outperform" rating in a report on Friday, November 8th. Wedbush dropped their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a research note on Friday, August 9th. Oppenheimer upped their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a research report on Monday, November 11th. Finally, Robert W. Baird started coverage on Dianthus Therapeutics in a report on Friday, July 26th. They issued an "outperform" rating and a $58.00 target price for the company. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $46.43.

Dianthus Therapeutics Stock Performance

The business has a fifty day moving average of $27.58 and a 200-day moving average of $26.68. The company has a market capitalization of $691.46 million, a P/E ratio of -9.34 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Quest Partners LLC grew its holdings in Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after buying an additional 1,124 shares in the last quarter. SG Americas Securities LLC purchased a new position in Dianthus Therapeutics during the 2nd quarter worth $112,000. The Manufacturers Life Insurance Company bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth $236,000. Fred Alger Management LLC raised its holdings in shares of Dianthus Therapeutics by 52.5% in the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company's stock valued at $264,000 after purchasing an additional 3,316 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new position in shares of Dianthus Therapeutics during the second quarter valued at about $265,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.